1. |
Ruddy KJ, Winer EP. Male breast cancer:risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol, 2013, 24(6):1434-1443.
|
2. |
Ly D, Forman D, Ferlay J, et al. An international comparison of male and female breast cancer incidence rates. Int J Cancer, 2013, 132(8):1918-1926.
|
3. |
程兆明, 蒋光愉, 曾颖, 等. 217077名妇女乳腺癌筛查结果分析.中华普通外科杂志, 2016, 31(4):328-332.
|
4. |
Korde LA, Zujewski JA, Kamin L, et al. Multidisciplinary meeting on male breast cancer:summary and research recommendations. J Clin Oncol, 2010, 28(12):2114-2122.
|
5. |
Serarslan A, Gursel B, Okumus NO, et al. Male breast cancer:20 years experience of a tertiary hospital from the middle black sea region of Turkey. Asian Pac J Cancer Prev, 2015, 16(15):6673-6679.
|
6. |
Chavez-Macgregor M, Clarke CA, Lichtensztajn D, et al. Male breast cancer according to tumor subtype and race a population-based study. Cancer, 2013, 119(9):1611-1617.
|
7. |
Dawood S. Updates from the 2014 San antonio breast cancer symposium. Indian J Med Paediatr Oncol, 2015, 36(1):66-70.
|
8. |
Johansson I, Killander F, Linderholm B, et al. Molecular profiling of male breast cancer-lost in translation. Int J Biochem Cell Biol, 2014, 53:526-535.
|
9. |
Korde LA, Zujewski JA, Kamin L, et al. Multidisciplinary meeting on male breast cancer:summary and research recommmendations. J Clin Oncol, 2010, 28(12):2114-2122.
|
10. |
De Juan I, Palanca S, Domenech A, et al. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study. Fam Cancer, 2015, 14(4):505-513.
|
11. |
Silvestri V, Barrowdale D, Mulligan AM, et al. Male breast cancer in BRCA1 and BRCA2 mutation carriers:pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res, 2016, 18(1):15.
|
12. |
Brinton LA, Cook MB, McCormack V, et al. Anthropometric and hormonal risk factors for male breast cancer:male breast cancer pooling project results. J Natl Cancer Inst, 2014, 106(3):djt465.
|
13. |
Humphries MP, Jordan VC, Speirs V. Obesity and male breast cancer:provocative parallels. BMC Med, 2015, 13:134.
|
14. |
Brinton LA, Key TJ, Kolonel LN, et al. Prediagnostic sex steroid hormones in relation to male breast cancer risk. J Clin Oncol, 2015, 33(18):2041-2050.
|
15. |
Grundy A, Harris SA, Demers PA, et al. Occupational exposure to magnetic fields and breast cancer among Canadian men. Cancer Med, 2016, 5(3):586-596.
|
16. |
Morrogh M, King TA. The significance of nipple discharge of the male breast. Breast J, 2009, 15(6):632-638.
|
17. |
Gradishar WJ, Anderson BO, Balassanian R, et al. Breast cancer version 2.2015. J Natl Compr Canc Netw, 2015, 13(4):448-475.
|
18. |
Graspari E, Ricci A, Liberto V, et al. An unusual case of mammary paget's disease diagnosed using dynamic contrast-enhanced MRI. Case Rep Radiol, 2013, 2013:206235.
|
19. |
刘新丽, 刘芳芳, 郑屹, 等.男性乳腺癌临床病理特征及预后分析.中国肿瘤临床, 2014, 41(23):1521-1526.
|
20. |
王翔宇, 方仪, 杨雪, 等.男性乳腺癌的临床病理特征及生存分析.临床肿瘤学杂志, 2016, 21(4):340-343.
|
21. |
Nilsson C, Koliadi A, Johansson I, et al. High proliferation is associated with inferior outcome in male breast cancer patients. Mod Pathol, 2013, 26(1):87-94.
|
22. |
马家芳, 乔昱, 丁丽, 等.男性乳腺癌患者临床病理特征及诊治分析.中华老年医学杂志, 2015, 34(7):790-792.
|
23. |
Leone JP, Leone J, Zwenger AO, et al. Prognostic significance of tumor subtypes in male breast cancer:a population-based study. Breast Cancer Res Treat, 2015, 152(3):601-609.
|
24. |
张志刚, 郭团魁, 周玉峰.男性乳腺癌临床病例分析.疾病监测与控制, 2016, 10(4):336-338.
|
25. |
韩娜, 王晓稼. 29例男性乳腺癌临床分析.分子诊断与治疗杂志, 2016, 8(1):23-26.
|
26. |
Abreu MH, Afonso N, Abreu PH, et al. Male breast cancer:looking for better prognostic subgroups. Breast, 2016, 26:18-24.
|
27. |
Zhou FF, Xia LP, Guo GF, et al. Changes in therapeutic strategies in Chinese male patients with breast cancer:40 years of experience in a single institute. Breast, 2010, 19(6):450-455.
|
28. |
李林, 朱明智, 邱新光.男性乳腺癌前哨淋巴结活检11例分析.国际外科学杂志, 2015, 42(3):171-173.
|
29. |
Maráz R, Boross G, Pap-Szekeres J, et al. The role of sentinel node biopsy in male breast cancer. Breast Cancer, 2016, 23(1):85-91.
|
30. |
Gnerlich JL, Deshpande AD, Jeffe DB, et al. Poorer survival outcomes for male breast cancer compared with female breast cancer may be attributable to in-stage migration. Ann Surg Oncol, 2011, 18(17):1837-1844.
|
31. |
Zaenger D, Rabatic BM, Dasher B, et al. Is breast conserving therapy a safe modality for early-stage male breast cancer. Clin Breast Cancer, 2016, 16(2):101-104.
|
32. |
Bratman SV, Kapp DS, Horst KC. Evolving trends in the initial locoregional management of male breast cancer. Breast, 2012, 21(3):296-302.
|
33. |
Atalay C, Kanlioz M, Altinok M. Prognostic factors affecting survival in male breast cancer. J Exp Clin Cancer Res, 2003, 22(1):29-33.
|
34. |
Yu E, Suzuki H, Younus J, et al. The impact of post-mastectomy radiation therapy on male breast cancer patients-a case series. Int J Radiat Oncol Biol Phys, 2012, 82(2):696-700.
|
35. |
Cutuli B, Le-Nir CC, Serin D, et al. Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases. Crit Rev Oncol Hematol, 2010, 73(3):246-254.
|
36. |
Giordano SH, Perkins GH, Broglio K, et al. Adjuvant systemic therapy for male breast carcinoma. Cancer, 2005, 104(11):2359-2364.
|
37. |
Sun B, Zhang LN, Zhang J, et al. The prognostic value of clinical and pathologic features in nonmetastatic operable male breast cancer. Asian J Androl, 2016, 18(1):90-95.
|
38. |
Untch M, Gerber B, Harbeck N, et al. 13th st. Gallen international breast cancer conference 2013:primary therapy of early breast cancer evidence, controversies, consensus-opinion of a german team of experts (zurich 2013). Breast Care (Basel), 2013, 8(3):221-229.
|
39. |
王丽娜, 严颖, 李惠平, 等.男性乳腺癌25例的临床病理特征及生存分析.癌症进展, 2014, 12(1):64-69.
|
40. |
Sousa B, Moser E, Cardoso F. An update on male breast cancer and future directions for research and treatment. Eur J Pharmacol, 2013, 717(1-3):71-83.
|
41. |
Zhou FF, Xia LP, Wang X, et al. Analysis of prognostic factors in male breast cancer:a report of 72 cases from a single institution. Chin J Cancer, 2010, 29(2):184-188.
|
42. |
Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med, 2002, 137(8):678-687.
|
43. |
Xu S, Yang Y, Tao W, et al. Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer. Breast Cancer Res Treat, 2012, 136(2):495-502.
|
44. |
Wenhui Z, Shuo L, Dabei T, et al. Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment. Eur J Endocrinol, 2014, 171(4):527-533.
|
45. |
Eggemann H, Ignatov A, Smith BJ, et al. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat, 2013, 137(2):465-470.
|
46. |
Pemmaraju N, Munsell MF, Hortobagyi GN, et al. Retrospective review of male breast cancer patients:analysis of tamoxifen-related side-effects. Ann Oncol, 2012, 23(6):1471-1474.
|
47. |
刘朋, 王芙荣, 纪立伟, 等. 212例他莫昔芬不良反应回顾性分析.中国药物应用与监测, 2011, 8(6):366-368.
|
48. |
Di Lauro L, Vici P, Del Medico P, et al. Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer. Breast Cancer Res Treat, 2013, 141(1):119-123.
|
49. |
Doyen J, Italiano A, Largillier R, et al. Aromatase inhibition in male breast cancer patients:biological and clinical implications. Ann Oncol, 2010, 21(6):1243-1245.
|
50. |
陈峰, 邱丽贞.芳香化酶抑制剂在早期男性乳腺癌治疗中的生物学效益及临床意义.中华医学杂志, 2014, 94(4):273-275.
|
51. |
Pritchard KI, Shepherd LE, Chapman J, et al. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women:NCIC CTG Ma.14. J Clin Oncol, 2011, 29(29):3869-3876.
|
52. |
Kuba S, Ishida M, Oikawa M, et al. Aromatase inhibitors with or without luteinizing hormone-releasing hormone agonist for metastatic male breast cancer:report of four cases and review of the literature. Breast Cancer, 2016, [Epub ahead of print].
|
53. |
Zagouri F, Sergentanis TN, Koutoulidis V, et al. Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer:a case series. Br J Cancer, 2013, 108(11):2259-2263.
|
54. |
Zagouri F, Sergentanis TN, Azim H Jr, et al. Aromatase inhibitors in male breast cancer:a pooled analysis. Breast Cancer Res Treat, 2015, 151(1):141-147.
|
55. |
Gucalp A, Tolaney S, Isakoff SJ, et al. Phase Ⅱ trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res, 2013, 19(19):5505-5512.
|
56. |
Di Leo A, Jerusalem G, Petruzelka L, et al. Final overall survival:fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst, 2014, 106(1):djt337.
|
57. |
Zagouri F, Sergentanis TN, Chrysikos D, et al. Fulvestrant and male breast cancer:a pooled analysis. Breast Cancer Res Treat, 2015, 149(1):269-275.
|
58. |
Hayashi H, Kimura M, Yoshimoto N, et al. A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatment. Breast Cancer, 2009, 16(2):136-140.
|